GlassScriptPhysician profile
William Troy Alexander
NPI 1114931854
$3,089.57
in general payments reported to CMS, 2019-2025
22 companies · $524 in 2025
The $524 reported for 2025 was more than what 78% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $212 · 2020: $190 · 2021: $642 · 2022: $819 · 2023: $543 · 2024: $160 · 2025: $524.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,227.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,226.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $457.92 | 2020-2025 | Tearcare System, Omni Surgical System |
| Sun Pharmaceutical Industries INC. | $336.79 | 2019-2025 | Cequa, Xelpros |
| Alcon Vision LLC | $329.41 | 2021-2025 | Total30 |
| Novartis Pharmaceuticals Corporation | $263.87 | 2021-2023 | |
| Oyster Point Pharma, INC. | $237.18 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $234.38 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $197.13 | 2021-2022 | |
| Bausch & Lomb Americas INC. | $187.62 | 2022-2025 | Vyzulta, Xiidra, Miebo |
| Allergan, INC. | $141.26 | 2019-2022 | |
| Abbvie INC. | $135.71 | 2022-2025 | Alphagan P, Lumigan, Vuity |
| Coopervision INC. | $98.85 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $93.72 | 2024-2025 | Xdemvy |
| Biotissue Holdings INC. | $84.74 | 2022 | |
| Apellis Pharmaceuticals, INC. | $66.04 | 2025 | Syfovre |
| Glaukos Corporation | $62.85 | 2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $44.72 | 2020-2021 | |
| Thea Pharma INC. | $27.31 | 2023 | |
| Maculogix, INC. | $24.35 | 2019 | |
| Horizon Therapeutics Plc | $21.77 | 2023 | Tepezza |
| Johnson & Johnson Vision Care, INC. | $16.13 | 2025 | |
| Eyevance Pharmaceuticals LLC | $15.30 | 2021 | |
| Ocular Therapeutix, INC. | $12.52 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Alexander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.